Y.D. More Investments Ltd Sells 60,039 Shares of Kamada Ltd. $KMDA

Y.D. More Investments Ltd lowered its stake in shares of Kamada Ltd. (NASDAQ:KMDA) by 18.2% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 269,665 shares of the biotechnology company’s stock after selling 60,039 shares during the period. Y.D. More Investments Ltd owned approximately 0.47% of Kamada worth $1,878,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Simplicity Wealth LLC purchased a new stake in Kamada in the 3rd quarter valued at about $70,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Kamada during the first quarter valued at approximately $206,000. Jump Financial LLC bought a new stake in Kamada during the second quarter worth $219,000. JPMorgan Chase & Co. lifted its holdings in Kamada by 43.6% during the third quarter. JPMorgan Chase & Co. now owns 40,984 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 12,442 shares during the period. Finally, NewEdge Advisors LLC boosted its position in Kamada by 119.9% in the first quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 28,165 shares during the last quarter. 20.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. HC Wainwright raised their price objective on shares of Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Wall Street Zen raised shares of Kamada from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a research note on Thursday, January 22nd. Finally, Benchmark reiterated a “buy” rating on shares of Kamada in a research note on Thursday, January 8th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.00.

Kamada Stock Up 0.5%

KMDA traded up $0.05 on Friday, hitting $8.71. The company’s stock had a trading volume of 2,814 shares, compared to its average volume of 78,279. Kamada Ltd. has a 12 month low of $5.54 and a 12 month high of $9.08. The firm has a market cap of $500.68 million, a P/E ratio of 24.32, a price-to-earnings-growth ratio of 0.75 and a beta of 0.94. The company’s 50 day simple moving average is $7.86 and its 200-day simple moving average is $7.26.

Kamada Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.